17,857 Shares in GSK PLC Sponsored ADR (NYSE:GSK) Acquired by Aurora Private Wealth Inc.

Aurora Private Wealth Inc. purchased a new position in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 17,857 shares of the pharmaceutical company's stock, valued at approximately $692,000.

A number of other institutional investors have also recently bought and sold shares of the business. FMR LLC increased its holdings in shares of GSK by 82.1% during the 4th quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company's stock worth $1,786,475,000 after acquiring an additional 23,814,104 shares during the last quarter. Primecap Management Co. CA increased its holdings in shares of GSK by 70.1% during the 4th quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company's stock worth $854,349,000 after acquiring an additional 10,407,905 shares during the last quarter. Voloridge Investment Management LLC increased its holdings in shares of GSK by 1,360.4% during the 4th quarter. Voloridge Investment Management LLC now owns 2,165,043 shares of the pharmaceutical company's stock worth $73,222,000 after acquiring an additional 2,016,795 shares during the last quarter. Bridgewater Associates LP increased its holdings in shares of GSK by 132.7% in the fourth quarter. Bridgewater Associates LP now owns 2,247,691 shares of the pharmaceutical company's stock valued at $76,017,000 after purchasing an additional 1,281,855 shares during the last quarter. Finally, Woodline Partners LP acquired a new position in shares of GSK in the fourth quarter valued at $36,665,000. Institutional investors and hedge funds own 15.74% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a report on Monday, April 28th. Wall Street Zen lowered shares of GSK from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Finally, BNP Paribas began coverage on GSK in a research report on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 target price on the stock. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a strong buy rating to the stock. According to MarketBeat, GSK currently has a consensus rating of "Hold" and a consensus price target of $37.38.

GSK Stock Performance

Shares of NYSE:GSK traded down $0.25 on Friday, reaching $38.26. 3,002,585 shares of the company's stock were exchanged, compared to its average volume of 4,939,201. The company has a fifty day moving average of $39.00 and a 200-day moving average of $37.11. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $44.67. The company has a market capitalization of $78.33 billion, a price-to-earnings ratio of 19.72, a PEG ratio of 1.53 and a beta of 0.50. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.21.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. The business had revenue of $10.06 billion for the quarter, compared to the consensus estimate of $7.52 billion. GSK had a return on equity of 48.82% and a net margin of 9.89%. The firm's quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.43 earnings per share. On average, research analysts predict that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be issued a dividend of $0.4216 per share. This is a positive change from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a dividend yield of 4.41%. The ex-dividend date is Friday, May 16th. GSK's dividend payout ratio is 87.11%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.